We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.17B
1-Year Est. Return 92.19%
This Fund
S&P 500
This Quarter Est. Return
+32.88%
1 Year Est. Return
+92.19%
3 Year Est. Return
+240.57%
5 Year Est. Return
+377.11%
10 Year Est. Return
+3,179.38%
AUM
$1.17B
AUM Growth
+$68.7M
Cap. Flow
+$9.42M
Cap. Flow %
0.81%
Top 10 Hldgs %
33.9%
Holding
116
New
34
Increased
23
Reduced
41
Closed
18

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$26.9M
2
ASND icon
Ascendis Pharma A/S
ASND
+$19M
3
MTD icon
Mettler-Toledo International
MTD
+$16.1M
4
MRK icon
Merck
MRK
+$14.9M
5
CYTK icon
Cytokinetics
CYTK
+$13.8M

Top Sells

Rank Stock Value
1
THC icon
Tenet Healthcare
THC
+$50M
2
LLY icon
Eli Lilly
LLY
+$27.1M
3
PEN icon
Penumbra
PEN
+$25.8M
4
GKOS icon
Glaukos
GKOS
+$23.2M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$21M

Sector Composition

Rank Sector Weight
1 Healthcare 98.83%
2 Miscellaneous 1.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MBX
76
MBX Biosciences
MBX
$2.97B
$3.92M 0.34%
70,971
-923
-1% -$32.2K
MIRM icon
77
Mirum Pharmaceuticals
MIRM
$6.15B
$3.69M 0.32%
+31,536
New +$3.17M
CGEM icon
78
Cullinan Oncology
CGEM
$1.42B
$3.5M 0.3%
192,442
-34,964
-15% -$519K
CMPS
79
Compass Pathways
CMPS
$1.84B
$3.5M 0.3%
247,589
-1,119,510
-82% -$11.4M
HCA icon
80
HCA Healthcare
HCA
$87.7B
$3.23M 0.28%
8,295
-5,056
-38% -$2.14M
CAPR icon
81
Capricor Therapeutics
CAPR
$547M
$2.94M 0.25%
122,221
-1,610
-1% -$48.8K
DNLI icon
82
Denali Therapeutics
DNLI
$3.56B
$2.6M 0.22%
+100,966
New +$2.07M
SNDX icon
83
Syndax Pharmaceuticals
SNDX
$1.84B
$2.59M 0.22%
118,422
-126,599
-52% -$2.63M
AMLX icon
84
Amylyx Pharmaceuticals
AMLX
$3.8B
$2.58M 0.22%
143,700
-1,575
-1% -$24.4K
TARS icon
85
Tarsus Pharmaceuticals
TARS
$3.98B
$2.55M 0.22%
40,579
-39,647
-49% -$2.53M
OM icon
86
Outset Medical
OM
$67.5M
$2.51M 0.22%
582,122
-12,508
-2% -$54.7K
OMDA
87
Omada Health Inc
OMDA
$1.39B
$2.51M 0.22%
+114,442
New +$1.83M
ERAS icon
88
Erasca
ERAS
$5.66B
$2.46M 0.21%
+134,088
New +$1.92M
COR icon
89
Cencora
COR
$63.2B
$2.09M 0.18%
+7,385
New +$2.13M
BCRX icon
90
BioCryst Pharmaceuticals
BCRX
$2.55B
$2.07M 0.18%
+207,357
New +$1.88M
OMCL icon
91
Omnicell
OMCL
$1.57B
$2.04M 0.17%
+49,040
New +$1.98M
CVRX icon
92
CVRx
CVRX
$81.3M
$1.9M 0.16%
+369,572
New +$2.39M
HIMS icon
93
Hims & Hers Health
HIMS
$6.47B
$1.71M 0.15%
+49,454
New +$1.33M
MLYS icon
94
Mineralys Therapeutics
MLYS
$2.49B
$1.68M 0.14%
62,418
-80,259
-56% -$2.2M
TECX
95
Tectonic Therapeutic
TECX
$601M
$1.57M 0.13%
45,631
-498
-1% -$14.6K
QURE icon
96
uniQure
QURE
$3.09B
$1.22M 0.1%
26,396
-16,239
-38% -$425K
RZLT icon
97
Rezolute
RZLT
$441M
$662K 0.06%
127,289
-1,437
-1% -$5.34K
CRBU icon
98
Caribou Biosciences
CRBU
$168M
$624K 0.05%
354,687
-603,100
-63% -$1.19M
ALHC icon
99
Alignment Healthcare
ALHC
$2.81B
– –
-359,826
Closed -$6.34M
ASND icon
100
CALL
Ascendis Pharma A/S
ASND
$17.7B
– –
-22,400
Closed -$5.12M
1 2 3
4
5

Similar funds

JC
Jacobs & Co San Francisco, California $1.17B AUM 37.3% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.16B AUM 28.78% 1-Year Est. Return
MK
MASTERINVEST Kapitalanlage Vienna $1.16B AUM 40% 1-Year Est. Return
HCP
Hiddenite Capital Partners New York $1.16B AUM 95.58% 1-Year Est. Return
EC
Estate Counselors Thiensville, Wisconsin $1.16B AUM 21.97% 1-Year Est. Return
M
MOTCO San Antonio, Texas $1.17B AUM 23.84% 1-Year Est. Return
CCM
Coliseum Capital Management Rowayton, Connecticut $1.16B AUM 23.26% 1-Year Est. Return
VFP
Verus Financial Partners Richmond, Virginia $1.17B AUM 15.91% 1-Year Est. Return

PFM Health Sciences's Q2 2026 Portfolio in Review

As of Q2 2026, PFM Health Sciences held 116 positions worth $1.17B, up 6.3% from $1.1B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

PFM Health Sciences's Q2 2026 filing shows 34 new, 23 increased, 41 reduced and 18 closed positions. Its largest new stake was Humana: 94,375 shares worth $37.5M. The largest sale was Tenet Healthcare, an estimated $50M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 85% a quarter earlier, followed by Miscellaneous.

  • PFM Health Sciences's largest Q2 2026 buy was Humana: 94,375 shares worth $37.5M.
  • PFM Health Sciences added most to Ascendis Pharma A/S in Q2 2026, an estimated $19M increase.
  • PFM Health Sciences's biggest Q2 2026 reduction was Tenet Healthcare, cutting an estimated $50M.
  • PFM Health Sciences fully exited Glaukos in Q2 2026, selling an estimated $23.2M.
  • PFM Health Sciences's ten largest holdings make up 34% of its $1.17B portfolio in Q2 2026.
  • PFM Health Sciences opened 34 new positions and closed 18 in Q2 2026.
  • PFM Health Sciences's portfolio value rose 6.3% quarter-over-quarter to $1.17B.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.